Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
BioNTech's breast cancer drug meets its Phase 3 endpoint but serious lung toxicity raises concerns. Explore the results and approval outlook.
Pharma & Biotech